Literature DB >> 15174976

Application of Quillaja saponaria extracts as oral adjuvants for plant-made vaccines.

Dwayne D Kirk1, Rachel Rempel, Julia Pinkhasov, Amanda M Walmsley.   

Abstract

Extracts from the Quillaja saponaria tree are known to provide immune potentiating responses and, hence, can be useful as adjuvants. Partial purification from the crude (food-grade) extract results in Quil A, which is contained in several veterinary vaccines. Further purification can provide concentrated saponin fractions such as QS-21, which is currently under investigation as a potential adjuvant for use in humans. Purified saponins have proven safe and effective when injected and have significantly enhanced the efficacy of some oral vaccines under clinical investigation. Toxicity of the food-grade extract from Quillaja saponaria has limited its use as a parenteral adjuvant; however, this toxicity seems to be abated when delivered orally. It is commonly used within the food and beverage industries and has no documented toxicity in humans at the present levels of consumption. Use of transgenic plants has been proposed as an alternative system for oral vaccine production and administration, and it is likely that an oral adjuvant will be required in most cases. Food-grade saponins have significant advantages for use with plant-made vaccines and are likely to provide a broad adjuvant effect due to the multiple saponin components. A review of the origin, production, biological activity, toxicity and use in the food industry is provided for Quillaja saponaria extract. Previous evaluation of this adjuvant in preclinical studies with plant made vaccines is discussed and a proposed level of experimental use in humans is provided.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15174976     DOI: 10.1517/14712598.4.6.947

Source DB:  PubMed          Journal:  Expert Opin Biol Ther        ISSN: 1471-2598            Impact factor:   4.388


  8 in total

1.  Evaluation of three experimental bovine viral diarrhea virus killed vaccines adjuvanted with combinations of Quil A cholesterol and dimethyldioctadecylammonium (DDA) bromide.

Authors:  Julia F Ridpath; Paul Dominowski; Ramasany Mannan; Robert Yancey; James A Jackson; Lucas Taylor; Sangita Mediratta; Robert Eversole; Charles D Mackenzie; John D Neill
Journal:  Vet Res Commun       Date:  2010-09-28       Impact factor: 2.459

2.  Re-evaluation of Quillaia extract (E 999) as a food additive and safety of the proposed extension of use.

Authors:  Maged Younes; Gabriele Aquilina; Laurence Castle; Karl-Heinz Engel; Paul Fowler; Maria Jose Frutos Fernandez; Peter Fürst; Rainer Gürtler; Ursula Gundert-Remy; Trine Husøy; Wim Mennes; Agneta Oskarsson; Romina Shah; Ine Waalkens-Berendsen; Detlef Wölfle; Polly Boon; Claude Lambré; Paul Tobback; Matthew Wright; Ana Maria Rincon; Camilla Smeraldi; Alexandra Tard; Peter Moldeus
Journal:  EFSA J       Date:  2019-03-06

3.  Integrated metabolomics identifies CYP72A67 and CYP72A68 oxidases in the biosynthesis of Medicago truncatula oleanate sapogenins.

Authors:  Vered Tzin; John H Snyder; Dong Sik Yang; David V Huhman; Bonnie S Watson; Stacy N Allen; Yuhong Tang; Karel Miettinen; Philipp Arendt; Jacob Pollier; Alain Goossens; Lloyd W Sumner
Journal:  Metabolomics       Date:  2019-05-29       Impact factor: 4.290

4.  Zinc Lactate and Sapindin Act Synergistically with Lactocin 160 Against Gardnerella vaginalis.

Authors:  Yevgeniy Turovskiy; Michael L Chikindas
Journal:  Probiotics Antimicrob Proteins       Date:  2011-06-01       Impact factor: 4.609

5.  An interspecific Nicotiana hybrid as a useful and cost-effective platform for production of animal vaccines.

Authors:  Huai-Yian Ling; Aaron M Edwards; Michael P Gantier; Kathleen D Deboer; Alan D Neale; John D Hamill; Amanda M Walmsley
Journal:  PLoS One       Date:  2012-04-23       Impact factor: 3.240

6.  Risk analysis for plant-made vaccines.

Authors:  Dwayne D Kirk; Kim McIntosh; Amanda M Walmsley; Robert K D Peterson
Journal:  Transgenic Res       Date:  2005-08       Impact factor: 2.788

7.  Protective effect of ginsenoside-Rb2 from Korean red ginseng on the lethal infection of haemagglutinating virus of Japan in mice.

Authors:  Yung Choon Yoo; Junglim Lee; Seok Rae Park; Ki Yeul Nam; Young Ho Cho; Jae Eul Choi
Journal:  J Ginseng Res       Date:  2013-03       Impact factor: 6.060

8.  QS-21: A Potent Vaccine Adjuvant.

Authors:  Daming Zhu; Wenbin Tuo
Journal:  Nat Prod Chem Res       Date:  2015-07-31
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.